Subscribe To

Price Alert Latest News Economic Calendar News

NVAX / Novavax initiates trial of COVID-flu combination vaccine candidate

Novavax Inc. NVAX, +7.28% said Friday that it has initiated a Phase 2 trial for its COVID-19-Influenza Combination (CIC) vaccine candidate, as well as for a stand-alone flu vaccine candidate. The biotechnology company said the trial will evaluate the safety and effectiveness of different formulations of the CIC and flu vaccine candidates in peopled aged 50 through 80. Read More

Demo Live Account See Partner Details

Content Topics

Novavax

Initiates

Trial

Covid

Flu

Combination

Vaccine

Covid flu

Candidate

Stock

NVAX

Posted: Dec 30 2022, 08:13

Author Name: Market Watch

NVAX News

By Invezz
November 3, 2023

Novavax could become a penny stock: beware of the Wyckoff theory

Novavax (NASDAQ: NVAX) stock price has been a huge disappointment among investors in the past few months. After peaking at $332 during the Covid-19 pa

By PRNewsWire
November 2, 2023

Novavax to Host Conference Call to Discuss Third Quarter 2023 Financial Results and Operational Highlights on November 9, 2023

GAITHERSBURG, Md. , Nov. 2, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™

By Reuters
October 16, 2023

Novavax positive on updated COVID vaccine availability in US

Novavax said on Monday it was "encouraged" by the broad availability of its updated COVID-19 vaccine being rolled out in the U.S., days after rival Pf

By The Motley Fool
October 16, 2023

Is Novavax Stock a Buy Now?

Novavax's coronavirus vaccine is one of the few currently authorized in the U.S. However, the company's competition is fierce in a market whose size i

By Reuters
October 15, 2023

EU delays approval of Novavax's revised COVID vaccine - FT

European Union (EU) regulators have delayed the decision to give approval for Novavax's variant-tailored COVID-19 vaccine, the Financial Times said on

By InvestorPlace
October 13, 2023

Novavax (NVAX) Stock Slides Despite Vaccine Availability

Despite seemingly good news, shares of biotechnology firm Novavax (NASDAQ: NVAX ) suffered a significant decline. Earlier Friday morning, management a

By Reuters
October 13, 2023

Novavax's updated COVID-19 vaccines available in US pharmacies

Novavax said on Friday its updated COVID-19 vaccine was available across pharmacies in the United States.

By Zacks Investment Research
October 10, 2023

Novavax (NVAX) Focuses on Diversifying Vaccines Portfolio

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indicatio

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.